Current Smoker, Malignant Neoplasm
Conditions
Brief summary
This pilot clinical trial studies how well the JeffQuit group therapy program works in enabling patients with a history of cancer to quit smoking. The JeffQuit program uses group therapy to provide psychological support and address the mental need for smoking, the habit or routine it creates, and the physical need for nicotine. It is not yet known how well the JeffQuit program will work in helping patients with a history of cancer to stop smoking.
Detailed description
PRIMARY OBJECTIVES: I. To assess the initial effectiveness of the JeffQuit program on smoking cessation in cancer patients. II. To assess the quality of life improvements related to the JeffQuit smoking cessation program in cancer patients. OUTLINE: Patients undergo three, 1-hour group therapy sessions held by a JeffQuit practitioner over a 1-month period. Patients receive strategies for managing the psychological, habitual, and physiological components of smoking and help with developing a planned quit date. Patients are also provided with advice on how to switch to cigarette brands with less nicotine and then how to substitute the nicotine patch and gum for cigarettes. The JeffQuit counselor is available for additional individual support as needed. After completion of study, patients are followed up at 6 months.
Interventions
Undergo JeffQuit group therapy
Undergo JeffQuit group therapy
OTHERQuality-of-Life Assessment
Ancillary studies
Sponsors
Sidney Kimmel Cancer Center at Thomas Jefferson University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. History of cancer 2. Current smoker 3. Willing to provide consent and participate in the JeffQuit program 4. Referral by a Kimmel Cancer Center provider
Exclusion criteria
1. Any significant active medical disorder or physical condition that could reasonably be expected to interfere with the ability of the patient to quit smoking as determined by the Principal Investigator (PI) 2. Currently participating in another smoking cessation program 3. Currently receiving chemotherapy or radiation therapy that would interfere with their ability to participate in the JeffQuit program 4. Patients with evidence of a significant psychiatric disorder by history/examination that would prevent completion of the study will not be allowed to participate 5. Patients with current alcohol or drug abuse 6. Enrollment in active clinical trial/ experimental therapy within the prior 30 days 7. Are in the terminal stages of illness
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients who are adherent to smoking abstinence | Up to 6 months after completion of intervention | Calculated along with a 1-sided 95% exact confidence interval. An exact binomial test (with a one-sided alpha of 0.05) will also be used to test whether adherence is greater than 60%. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Patient Reported Outcomes Measurement Information System (PROMIS) quality of life scores | Baseline to up to 6 months after completion of intervention | The scores for the Patient Reported Outcomes Measurement Information System (PROMIS) questionnaire will be evaluated for differences between the pre and post program states using analysis of variance using mixed models to allow for inclusion of all subjects with at least one measurement, with assessment of post-treatment to pre-treatment changes as the primary consideration. Longitudinal repeated measures using linear mixed models will be applied to assess the change from baseline as the outcome, and an exploratory analysis of potential clinical and demographic modifiers will be completed. |
| Change in Smoking Cessation Quality of Life (SCQoL) questionnaire scores | Baseline to up to 6 months after completion of intervention | The scores for the Smoking Cessation Quality of Life (SCQoL) questionnaire will be evaluated for differences between the pre and post program states using analysis of variance using mixed models to allow for inclusion of all subjects with at least one measurement, with assessment of post-treatment to pre-treatment changes as the primary consideration. Longitudinal repeated measures using linear mixed models will be applied to assess the change from baseline as the outcome, and an exploratory analysis of potential clinical and demographic modifiers will be completed. |
Countries
United States
Outcome results
None listed